MARKET

TTPH

TTPH

Tetraphase
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.470
+0.010
+0.41%
Closed 16:00 11/15 EST
OPEN
2.450
PREV CLOSE
2.460
HIGH
2.584
LOW
2.360
VOLUME
80.94K
TURNOVER
--
52 WEEK HIGH
39.60
52 WEEK LOW
2.260
MARKET CAP
6.71M
P/E (TTM)
-0.0040
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TTPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TTPH News

  • The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
  • Benzinga.9h ago
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.1d ago
  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.2d ago
  • Tetraphase Pharmaceuticals EPS beats by $0.70, misses on revenue
  • seekingalpha.2d ago

More

Industry

Pharmaceuticals
+1.25%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Name
Price
%Change

About TTPH

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
More

Webull offers Tetraphase Pharmaceuticals Inc (TTPH) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.